Press Releases

Year

July 9, 2020

Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and commercial plans -- BRIDGEWATER, N.J , July 09, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals

June 30, 2020

Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration

-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80 mg/day -- BRIDGEWATER, N.J. , June 30, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq:

June 16, 2020

Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit

BRIDGEWATER, N.J. , June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present

May 27, 2020

Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

BRIDGEWATER, N.J. , May 27, 2020 /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results of the Company's Annual General Meeting. At the Annual General Meeting of the Company held on May 20,

May 26, 2020

Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference

BRIDGEWATER, N.J. , May 26, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at

May 13, 2020

Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

BRIDGEWATER, N.J. , May 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at

May 12, 2020

Osmotica Pharmaceuticals plc Reports First Quarter 2020 Results and Provides Business Updates

First quarter 2020 total revenue of $48.6 million On track to achieve major 2020 milestones BRIDGEWATER, N.J. , May 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business

May 8, 2020

Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020

BRIDGEWATER, N.J. , May 08, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 first quarter financial results on Tuesday, May 12, 2020 , after the

March 18, 2020

Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2019 Results and Provides Business Updates

Fourth quarter and full year 2019 total revenue of $59.9 million and $240.0 million , respectively New Drug Application accepted by FDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid; user fee goal date of July 16, 2020 Completed a

March 12, 2020

Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2019 Business and Financial Update on March 18, 2020

BRIDGEWATER, N.J. , March 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 fourth quarter and full year financial results on Wednesday, March

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 14

Investor Relations

News

Press Releases

Press Releases

Press Releases